Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer: Interpretation of Breast Cancer Research Hotspots in 2024 ASCO

Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer: Interpretation of Breast Cancer Research Hotspots in 2024 ASCO

HR-positive HER2-low breast cancer is a new hotspot therapeutic subtype, accounting for approximately 53.7% of all breast cancers. Patients with this type of cancer tend to have a high rate of lymph node metastasis and poor sensitivity to neoadjuvant chemotherapy and conventional anti-HER2 therapy,...

Full description

Bibliographic Details
Main Authors: Yiwen MA, Junnan XU, Tao SUN
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2025-02-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
hr-positive
her2-low expression
cdk4/6 inhibitors
t-dxd
breast cancer
Online Access:http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1033

Internet

http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1033

Similar Items